Reinaldo Rosario MD, FASN Renal Electrolyte & Hypertension Consultants (REHC)
CKD - DEFINITION
Evidence of structural or functional kidney abnormalities that persists for at least 3 months, with or without a decreased GFR. GFR <60 mL/min/1.73m for 3 months, with or without kidney damage Prevalence 4.7% or 8.3 million
II III
60-89
IV
V
15-29
<15
PREVALENCE OF CKD
8,000,000 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000,000 0 >90 60-89 30-59 15-29 <15 GFR (ml/min/1.73m2)
ESRD
As of Dec. 31 2006 506,256 dialysis pts In 2006 alone, 110,854 pts entered the ESRD program Medicare expenditure - $22.7 billion in 2006 Projected number of ESRD pts by 2010 651,330 and Medicare cost in excess of $28 billion dollars
ESRD
Annual mortality rate for all ESRD pts on treatment is 20-fold higher than the general population At age 45 life expectancy: - General population: 34.7 years - ESRD: 6.2 years on dialysis / 19.5 years with a functioning kidney graft
4%
Cardiac
39%
26%
DELAYED DIAGNOSIS OF CKD LEADS TO UNDERUSE OF INTERVENTIONS Lack of interventions to treat HTN, CVD, DM, anemia, and malnutrition Under use and delayed consultations with nephrologists, cardiovascular specialists, or dietitians Lack of patient education Lack of a permanent vascular access at initiation of hemodialysis
Prevent complications
Anemia Malnutrition Osteodystrophy Acidosis
Treat comorbidities
Cardiac disease Vascular disease Diabetes
Prepare or RRT
Educate patient Select RRT modality Create access and initiate dialysis in a timely fashion
17%
1795 patients with kidney diseases were screened GFR range 13-55 mL/min/1.73m BP in 83% of patients (n=1494)
Hypertensive
83%
Patient Type
Diabetes
ISHIB(Isolated Systolic Hypertension in Blacks) Uncomplicated HTN With DM, CKD Albuminuria (>300 mg/d or >200 mg/g creatinine), with or without diabetes Low risk for CVDPresence of Diabetes Mellitus, target organ damage
SBP<140 <130/80
SBP
<125
DBP
<75
<135
<85
CKD stage 5
<140
<90
GFR = BP MEDS
4 3.5 3 2.5 2 1.5 1 0.5 0 90-99 80-89 70-79 60-69 50-59 40-49 GFR Diabetic Studies Non-Diabetic Studies
BP CONTROL: INTERVENTIONS
ACE inhibitors Angiotensin-receptor blockers (ARBs) Calcium channel blockers (CCBs) Diuretics Low-sodium diet Combination therapy
increase in the number of diabetics. 25 to 40% of these individuals will develop kidney disease. Obesity, poor dietary habits, lack of physical activity, family history are risks.
diabetes 32.8% males, 38.5% females. Hispanic lifetime risk 45.4% males, 52.5% females.
No data available
Less than 4%
4%6%
Above 6%
4%6%
*Includes women with a history of gestational diabetes.
Mokdad AH et al. JAMA. 2001;286(10):1195-1200.
Above 6%
the United States 40-50% of TYPE 1 Patients and 40% of TYPE 2 Patients will develop clinical diabetic kidney disease. Diabetes affects certain ethnic groups more frequently than caucasians: native americans 7x, hispanics and latinos 4-5x, african americans 4x.
39%
52%
43% 57%
EVALUATION OF ANEMIA
Hemoglobin and/or hematocrit Red-blood-cell indices Reticulocyte count Iron parameters Test for occult-blood in stool
TREATMENT OF ANEMIA
Iron supplementation (IV/PO) Erythropoiesis stimulating agents
NKF. Am J Kidney Dis. 2001;37 (suppl 1):S182 Silverberg. Kidney Int. 1999;55(suppl 69):S79
30 20 10
CrCl
0 >50 35 - 49 25 - 34 <25
Mean Hb (g/dL)
14.1
13.2
12.5
11.4
Greaves. Am J Kid Dis. 1994; 24;768 Levin. Am J Kid Dis. 1996; 27:347.
CHOIR Study
(Correction of Hemoglobin and Outcomes in Renal Insufficiency)
Study Objective: Whether a normal or near-normal Hb value should be the target level in pre-dialysis pts with CKD Study Design: 1432 CKD patients (eGFR 15-50 mL/min) with Hb < 11g/dL Primary Endpoint: Composite of death, myocardial infarction, stroke, and hospitalization for heart failure Methods: Randomization to achieve target Hb of either 13.5 or 11.3g/dL Results: Study terminated early(16 months) due to higher number of events in the high Hb group.
Drueke, TB et al. N Engl J Med 2006;355:2071
CREATE Study
(Cardiovascular Risk Reduction by Early Anemia Treatment with Epoietin Beta)
Study Objective: Whether a normal or near-normal Hb value should be the target level in pre-dialysis pts with CKD. Study Design: 603 pts with GFRs between 15-35 mL/min Primary Endpoint: Composite of eight CV events Methods: Randomization to normal Hb (13-15 g/dL) or subnormal (10.5 11.5 g/dL) Results: At 3 years similar risk of experiencing the primary endpoint in bot groups ( HR of 0.78, 95% CI 0.53-1.14)
Singh, AK et al. N Engl J Med 2006; 355:2085
SECONDARY HYPERPARATHYROIDISM
Most common form of renal osteodystrophy Prevalence 47% of 176 patients with ESRD had a PTH level more than three times the normal amount
Mizumoto. Nephrol Dial Transplant. 1994:9:1751 Billa. Perit Dial Int. 2000;20:315
Hyperphosphatemia
Begins early in renal disease Intimately related to secondary hyperparathyroidism which contributes to release of calcium and phosphorus from bone Elevated Ca x PO4 promotes precipitation of such in arteries, joints, soft tissues and the vicera Ca x PO4 >55 associated with increased mortality, similar to that observed with elevated PO4 level alone
Menon, V. Am J Kidney Dis 2005; 46:455.
MANAGEMENT OF VITAMIN D DEFICIENCY AND PHOSPHATE RETENTION Vitamin D analogs Low phosphate diet (800 mg/day) Phosphate binders (calcium and non-calcium based) Calcium
Coburn. J Am Soc Nephrol. 1998;9:S71 Schroeder. Nephrol Dial Transplant. 2000;15:460 Chertow. Clin Nephrol. 1999;51:18
Phosphate Binders
PO4 Binder Blood Ca Blood PO4 Blood level LDL Adverse Effects Calcium acetate Promotes coronary artery calcification Promotes coronary artery calcification Metabolic acidosis; not seen with Renvela Not yet reported
Calcium Carbonate
Renagel/ Renvela
Lanthanum
Aluminum
ACID/BASE BALANCE
Renal NH4+ Excretion 40 mEq/day Endogenous H+ Production 70 mEq/day Renal Excretion 30 mEq/day Renal Net Acid Excretion 70 mEq/day
CONSEQUENCES OF METABOLIC
ACIDOSIS
Abnormal renal handling of ions
tubular-phosphate reabsorption filtered load of calcium and phosphate tubular-calcium reabsorption
EXERCISE
Physical functioning Blood pressure control Muscle, bone strength Level of cholesterol and triglycerides Better sleep Control of body weight
NKF. Staying fit with Kidney Disease
Nephrologists Assist in development of care strategy Aid recommendation and implementation of patient care Provide role-specific patient education